AAAAAA

   
Results: 1-10 |
Results: 10
Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients
Authors: Lissoni, P Fumagalli, E Malugani, F Ardizzoia, A Bucovec, R Tancini, G Gardani, GS
Citation: P. Lissoni et al., Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients, J BIOL REG, 15(2), 2001, pp. 163-165
Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2
Authors: Lissoni, P Mandala, M Curigliano, G Ferretti, G Moro, C Ardizzoia, A Malugani, F Tancini, G Tisi, E Arrigoni, C Barni, S
Citation: P. Lissoni et al., Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2, ONCOL-BASEL, 60(4), 2001, pp. 308-312
Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer
Authors: Lissoni, P Fugamalli, E Malugani, F Ardizzoia, A Secondino, S Tancini, G Gardani, GS
Citation: P. Lissoni et al., Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer, INT J B MAR, 15(4), 2000, pp. 308-311
Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia
Authors: Lissoni, P Mandala, M Rovelli, F Casu, M Rocco, F Tancini, G Scardino, E
Citation: P. Lissoni et al., Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia, EUR UROL, 37(5), 2000, pp. 569-572
Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients
Authors: Bordin, V Giani, L Meregalli, S Bukovec, R Vaghi, MM Mandala, M Paolorossi, F Ardizzoia, A Tancini, G Barni, S Frigerio, F Fumagalli, L Bordoni, A Valusani, G Di Felice, G Lissoni, P
Citation: V. Bordin et al., Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients, UROL INTERN, 64(1), 2000, pp. 3-8
Decreased toxicity and increased efficacy of cancer chemotherapy using thepineal hormone melatonin in metastatic solid tumour patients with poor clinical status
Authors: Lissoni, P Barni, S Mandala, M Ardizzoia, A Paolorossi, F Vaghi, M Longarini, R Malugani, F Tancini, G
Citation: P. Lissoni et al., Decreased toxicity and increased efficacy of cancer chemotherapy using thepineal hormone melatonin in metastatic solid tumour patients with poor clinical status, EUR J CANC, 35(12), 1999, pp. 1688-1692
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: A phase II study
Authors: Lissoni, P Tancini, G Paolorossi, F Mandala, M Ardizzoia, A Malugani, F Giani, L Barni, S
Citation: P. Lissoni et al., Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: A phase II study, J PINEAL R, 26(3), 1999, pp. 169-173
Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease
Authors: Lissoni, P Vigore, L Ferranti, R Bukovec, R Meregalli, S Mandala, M Barni, S Tancini, G Fumagalli, L Giani, L
Citation: P. Lissoni et al., Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease, J BIOL REG, 13(4), 1999, pp. 216-219
Endocrinological study of the dopaminergic regulation of prolactin releasein metastatic breast cancer
Authors: Mandala, M Lissoni, P Ardizzoia, A Barni, S Rovelli, F Confalonieri, G Malugani, F Moro, C Fumagalli, G Giani, L Tancini, G
Citation: M. Mandala et al., Endocrinological study of the dopaminergic regulation of prolactin releasein metastatic breast cancer, TUMORI, 85(6), 1999, pp. 494-497
Long-term results of cancer immunotherapy with subcutaneous low-dose interleukin-2 plus melatonin
Authors: Lissoni, P Laudon, M Barni, S Brivio, F Tisi, E Rovelli, F Chatikhine, V Fumagalli, L Maestroni, GJM Conti, A Tancini, G
Citation: P. Lissoni et al., Long-term results of cancer immunotherapy with subcutaneous low-dose interleukin-2 plus melatonin, INT J IMM T, 14(3), 1998, pp. 169-174
Risultati: 1-10 |